Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and complex therapies, announced that it will hold a two-day symposium, entitled “We Know Nano”, on Tuesday, September 15 to Wednesday, September 16, 2026, at the Dome-X in Oss, The Netherlands. Experts and speakers from Ardena will be joined by a number of external speakers from innovative biotechnology companies working in the field of nanotechnology.

This event has been designed to be a valuable resource for researchers, drug developers, C-suite executives of biotech companies, and regulatory affairs professionals. The agenda is split into in four specific sessions: clinical research; payload development; delivery mechanisms; and analysis. Each will include presentations from experts in the field, and a panel discussion for delegates to discuss the latest development in nanomedicine research with the speakers.

Confirmed external speakers include:

• Dr. Christian Schröter, Chief Operating Officer of Topas Therapeutics, Germany

• Dr. Glenn Meyer, Product Development Specialist at Peptinovo Biopharma, USA

• Dr. Morten Petersen, Chief Development Officer at MonTa Biosciences, Denmark

• Denis Cecchin, Chief Technology Officer at ViaNautis, UK

• Prof. dr. Twan Lammers, Department of Nanomedicine and Theranostics Institute for Experimental Molecular Imaging RWTH Aachen University, Germany

• Dr. Sander van Berkel, Independent Consultant, The Netherlands

There will also be the opportunity for attendees to tour Ardena’s nanomedicine development facility in Oss after the event. Full details of the agenda and information on how to register for the event can be found here: https://ardena.com/we-know-nano-event/